<?xml version='1.0' encoding='utf-8'?>
<document id="18503057"><sentence text="Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy." /><sentence text="There are growing data suggesting a clinical relevance of residual platelet aggregation (RPA) in patients undergoing PCI" /><sentence text=" Drug-drug interaction of statins and clopidogrel has been controversially discussed in ex vivo studies and clinical trials"><entity charOffset="38-49" id="DDI-PubMed.18503057.s3.e0" text="clopidogrel" /></sentence><sentence text=" The aim of the present study was to investigate the effects of peri-procedural statin medication on the metabolization of aspirin and clopidogrel with regard to platelet aggregation and clinical outcome in patients undergoing coronary intervention"><entity charOffset="123-130" id="DDI-PubMed.18503057.s4.e0" text="aspirin" /><entity charOffset="135-146" id="DDI-PubMed.18503057.s4.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.18503057.s4.e0" e2="DDI-PubMed.18503057.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18503057.s4.e0" e2="DDI-PubMed.18503057.s4.e1" /></sentence><sentence text="" /><sentence text="Patients with coronary stenting for symptomatic coronary artery disease are routinely evaluated by platelet function analysis in a monocentre registry, and for the present study, a consecutive cohort of 1155 patients were analysed" /><sentence text=" About 87" /><sentence text="7% of the patients were treated with statins at the time of platelet function analysis" /><sentence text=" Residual platelet activity assessed by adenosine diphosphate (20 micromol/L)-induced platelet aggregation was not significantly influenced by statin treatment"><entity charOffset="40-61" id="DDI-PubMed.18503057.s9.e0" text="adenosine diphosphate" /></sentence><sentence text=" Nor the significant effects of CYP3A4-metabolization pathway on post-treatment aggregation were recorded, although there was even a trend to lower RPA values in patients treated with CYP3A4-metabolized statins" /><sentence text=" Further, in an inter-individual analysis comparing patients treated with CYP3A4- and non-CYP3A4-metabolized statins, no time-dependent difference of clopidogreĺs anti-aggregatory effects was observed"><entity charOffset="150-162" id="DDI-PubMed.18503057.s11.e0" text="clopidogreĺs" /></sentence><sentence text=" Clinical follow-up of major adverse events (myocardial infarction, ischaemic stroke, death) in 991 patients within 3 months revealed no significant adverse effects of statin treatment on clinical outcome" /><sentence text=" Instead, statin treatment was independently associated with lower incidence of composite events (HR 0" /><sentence text="44, 95% confidence interval 0" /><sentence text="23-0" /><sentence text="83, P = 0" /><sentence text="01)" /><sentence text="" /><sentence text="Peri-procedural co-administration of statins does not increase the post-interventional RPA in cardiovascular patients treated with dual antiplatelet therapy and does not worsen the clinical prognosis of these patients" /><sentence text="" /></document>